Search results
New PET agent provides same-day imaging for clear cell renal cell carcinoma patients
Medical Xpress· 9 hours agoA novel investigational PET imaging agent can rapidly and accurately visualize lesions in clear cell renal cell cancer (ccRCC) patients according to new research published in the May issue of ...
Massive study identifies new biomarkers for renal cancer subtypes, improving diagnosis and—...
Newswise· 2 days agoA new study led by University of Michigan Health Rogel Cancer Center researchers identifies novel...
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients - British...
Nature· 4 days agoTregs trafficking is controlled by CXCR4. In Renal Cell Carcinoma (RCC), the effect of the new CXCR4 antagonist, R54, was explored in ...
Good to Know: Grim diagnosis spurs Kent couple to sell possessions, plan RV trip of a lifetime
Akron Beacon Journal via Yahoo News· 2 days agoBut a scan last summer found new growth and Dailey had surgery to remove tumors on the kidney. And...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 6 days agoModerna detailed plans for its individual neoantigen cancer vaccine in a first-quarter earnings...
Afinitor interactions: Other medications, alcohol, and more
Medical News Today· 5 days agoAfinitor has interactions with some other drugs and certain supplements. Before you start treatment...
Fighting Cancer: A Basic Guide To Checkpoint Inhibitors
Forbes· 2 days agoThis article is part of an ongoing series on novel cancer advances, including immunotherapies such...
Short Interest in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Rises By 5.6%
ETF DAILY NEWS· 6 days agoIovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 48,980,000 shares ...
Exelixis (NASDAQ:EXEL) Earns “Outperform” Rating from William Blair
ETF DAILY NEWS· 4 days agoWilliam Blair reaffirmed their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a report published on Wednesday, RTT News reports. Barclays lowered Exelixis from an overweight ...
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks via Yahoo Finance· 6 days agoModerna/Merck also started two separate mid-stage studies in renal cell carcinoma and...